• In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores in cirrhotic patients, and reduced liver stiffness in routine clinical practice.
• These findings highlight Rezdiffra’s potential to address both liver disease progression and broader cardiometabolic risk, adding clinical depth beyond traditional histologic endpoints in MASH.
• We’ll now examine how this new evidence of Rezdiffra improving atherogenic lipid profiles could influence Madrigal’s wider investment narrative.

Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

Madrigal Pharmaceuticals Investment Narrative Recap

To own Madrigal today, you need to believe Rezdiffra can become a foundational MASH therapy and that the company can manage high spending and rising competition. The EASL data reinforcing both liver and cardiovascular risk benefits appear supportive of the near term catalyst around broader clinical uptake and potential label expansion, while modestly easing (but not eliminating) concern that outcomes in more advanced F4c disease could disappoint.

Among recent announcements, Madrigal’s new Phase 3 and real world evidence presented at EASL 2026 is most relevant here, because it ties directly to the key risk of dependence on Rezdiffra and the potential upside of expanding its use across the MASH spectrum. By strengthening the case that Rezdiffra improves atherogenic lipids and noninvasive liver markers, these data could influence how investors frame future outcomes readouts and payer discussions.

Yet despite the encouraging data, investors should still be aware that...

Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $671.07 fair value, a 37% upside to its current price.

Exploring Other Perspectives

While consensus focuses on Rezdiffra execution and spending risk, the most optimistic analysts were already assuming about US$3.6 billion of 2028 revenue and US$1.5 billion of earnings, so fresh EASL data could either reinforce or force a rethink of that far more ambitious view.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 6% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.